8-Week Long-Acting Injectable HIV Treatment Succeeds, is Moving to Advanced Trials

A long-acting injectable HIV treatment of cabotegravir and Edurant (rilpivirine), dosed every 4 or 8 weeks, succeeded in a recent trial.